CTOs on the Move

Recro

www.recrocdmo.com

 
Recro is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients` pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Funding

Recro raised $30M on 05/12/2021

Similar Companies

Altegra Health

Altegra Health is a national provider of technology-enabled, end-to-end payment solutions that enable health plans and other risk-bearing organizations to generate, analyze and submit the data needed to successfully manage member care and ensure appropriate reimbursement. The power of Altegra Health’s advanced analytics and supporting interventions enables healthcare organizations to elevate care quality, optimize financial performance, and enhance the member experience.

Renaissance Lakewood

Renaissance Pharmaceuticals is Your Partner for Nasal Sprays and Sterile Solutions. Trusted, Reliable, Contract Development, and Manufacturing.

Oratech

Oratech is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HemoCORM

HemoCORM is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tetraphase

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase`s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol `TTPH.` Tetraphase is well positioned to be a major player in the multidrug-resistant arena.